Carotid space involvement is a prognostic factor and marker for induction chemotherapy in patients with nasopharyngeal carcinoma

• Published in: Oral oncology 2022-12, Vol.135, p.106230-106230, Article 106230
• Main Authors: Quan, Tingting, Guan, Wenlong, Huang, Wenjie, Cui, Chunyan, Li, Haojiang, Ruan, Guangying, Liu, Lizhi, Zhao, Qin, Ma, Huali
• Format: Article
• Language: English
• Subjects: Carotid space involvement; Humans; Induction Chemotherapy; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Carcinoma - pathology; Nasopharyngeal Neoplasms - pathology; Neoplasm Staging; Overall survival; Parapharyngeal Space; Prognosis; Prognostic factor; Retrospective Studies
• ISSN: 1368-8375; 1879-0593
• DOI: 10.1016/j.oraloncology.2022.106230

•CSI was a negative factor for OS in NPC patients without ICT.•ICT significantly improved OS in NPC patients with CSI.•CSI may be an imaging marker for identifying eligible candidates for ICT. The carotid space is an integral part of the parapharyngeal space, with ambiguous prognostic value for patients with nasopharyngeal carcinoma (NPC). This study aimed to investigate the prognostic significance of carotid space involvement (CSI) and propose a treatment strategy. This retrospective study enrolled 792 patients with biopsy-confirmed, non-distant metastatic NPC staged by magnetic resonance imaging before treatment. We used multivariable Cox regression models and Kaplan–Meier methods to assess the association between the variables and survival outcomes. A matched-pair method (1:1) was used to compare the survival differences between the patients with CSI treated with induction chemotherapy (ICT)and that of those who were not. The incidence rate of CSI was 21.7 % (172/792). Multivariate analysis revealed that CSI was not an independent prognostic factor for survival outcomes in the 792 patients with NPC; however, the Chi-square test showed a different distribution of treatment strategies with ICT for patients with and without CSI. After stratification by ICT, CSI was an independent prognostic factor for overall survival (OS) (p = 0.049) in patients without ICT, but not for distant metastasis-free, local recurrence-free, or progression-free survival (p˃0.05). Additionally, ICT improved OS in patients with CSI (hazard ratio, 0.42; p = 0.019). Matched pair analysis showed that patients with CSI gained prolonged OS from ICT compared with the non-ICT group (88.4 % vs 69.4 %, p = 0.028). CSI was an independent negative prognostic factor for OS in patients with NPC without ICT and might be an imaging marker for identifying eligible candidates for ICT.